HRP20180762T1 - Liječenje karcinoma - Google Patents
Liječenje karcinoma Download PDFInfo
- Publication number
- HRP20180762T1 HRP20180762T1 HRP20180762TT HRP20180762T HRP20180762T1 HR P20180762 T1 HRP20180762 T1 HR P20180762T1 HR P20180762T T HRP20180762T T HR P20180762TT HR P20180762 T HRP20180762 T HR P20180762T HR P20180762 T1 HRP20180762 T1 HR P20180762T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- nuc
- leukemia
- treatment
- lymphoma
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 17
- 201000011510 cancer Diseases 0.000 title claims 16
- 238000011282 treatment Methods 0.000 title claims 11
- NHTKGYOMICWFQZ-BBOXMAMFSA-N fosgemcitabine palabenamide Chemical compound C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 NHTKGYOMICWFQZ-BBOXMAMFSA-N 0.000 claims 16
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000006994 Precancerous Conditions Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
1. NUC-1031 (gemcitabin-[fenil-benziloksi-L-alaninil)]-fosfat) za uporabu u ciljanju matičnih stanica karcinoma u liječenju karcinoma.
2. NUC-1031 za uporabu sukladno patentnom zahtjevu 1, naznačen time, što se koristi u liječenju recidiva ili refraktornog karcinoma kod čovjeka.
3. NUC-1031 za uporabu sukladno patentnom zahtjevu 2, naznačen time, što se koristi u liječenju recidiva karcinoma kod čovjeka.
4. NUC-1031 za uporabu sukladno bilo kojem prethodnih patentnih zahtjeva, naznačen time, da ciljanje matičnih stanica uzrokuje njihovu smrt.
5. NUC-1031 za uporabu u liječenju karcinoma sukladno bilo kojem od prethodnih patentnih zahtjeva smanjivanjem ili sprejčavanjem razvoja karcinoma.
6. NUC-1031 za uporabu u liječenju karcinoma sukladno bilo kojem od prethodnih patentnih zahtjeva smanjivanjem ili sprječavanjem progresije karcinoma.
7. NUC-1031 za uporabu u liječenju karcinoma sukladno bilo kojem od prethodnih patentnih zahtjeva smanjivanjem ili ponovnog pojavljivanja karcinoma.
8. NUC-1031 za uporabu u liječenju karcinoma sukladno bilo kojem od prethodnih patentnih zahtjeva smanjivanjem ili sprječavanjem širenja karcinoma
9. NUC-1031 za uporabu sukladno bilo kojem prethodnom patentnom zahtjevu u liječenju karcinoma odabranog iz skupine koja se sastoji od: leukemije, limfoma, multiple mijeloma, karcinoma pluća, karcinoma jetre, karcinoma dojke, karcinoma glave i vrata, neuroblastoma, tiroidnog karcinoma, karcinoma kože (uključujući melanom), oralnog karcinoma skvamoznih stanica, karcinoma mjehura, tumora Leydig-ovih stanica, karcinom žuči, kao što je kolangiokarcinom ili karcinom žučnog kanala, krcinom gušterače, karcinom debelog crijeva, kolorektalnog karcinoma, osteosarkoma i ginekoloških karcinoma, uključujući karcinom jajnika, karcinom endometrija, karcinom jajovoda, karcinom materniice i karcinom grlića maternice.
10. NUC-1031 za uporabu sukladno patentnom zahtjevu 9, pri čemu je leukemija odabrana iz skupine koja se sastoji od akutne limfoblastične leukemije, akutne mijelogene leukemije (također poznata kao akutna mijeloična leukemija ili akutna nelimfocitna leukemija), akutne promijelocitne leukemije, akutne limfocitne leukemije, kronične mijeloične leukemije (također poznata kao kronična mijeloična leukemija, kronična mijelocitna leukemija ili kronična granulocitna leukemija), kronične limfocitne leukemije, monoblastične leukemije i triholeukemije, osobito akutne limfoblastične leukemije.
11. NUC-1031 za uporabu sukladno patentnom zahtjevu 9, pri čemu je limfom odabran iz skupine koja se sastoji od: Hodgkin-ovog limfoma; ne-Hodgkin-ovog limfoma; Burkitt-ovog limfoma; i sitno-limfocitnog limfoma.
12. NUC-1031 uporabu sukladno bilo kojem prethodnom patentnom zahtjevu u tjednoj dozi od između 250 mg/m2 i 1000 mg/m2.
13. NUC-1031 za uporabu sukladno patentnom zahtjevu 12 u tjednoj dozi od između 375 mg/m2 i 900 mg/m2.
14. NUC-1031 za uporabu sukladno patentnom zahtjevu 13 u tjednoj dozi od između 500 mg/m2 i 825 mg/m2.
15. Postupak za određivanje da li će pacijent s karcinomom ili pre-kancerogenim stanjem imati korist od prevencije ili liječenja karcinoma s NUC-1031, pri čemu postupak sadrži: analiziranje biološkog uzorka reprezentativnog za karcinom ili pre-kancerogeno stanje kod pacijenta u prisutnosti CSCs; pri čemu prisutnost CSCs u biološkom uzorku ukazuje na to da će pacijent imati korist od liječenja s NUC-1031.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15726258.5A EP3197456B2 (en) | 2015-05-14 | 2015-05-14 | Cancer treatments |
| PCT/GB2015/051438 WO2016181093A1 (en) | 2015-05-14 | 2015-05-14 | Cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180762T1 true HRP20180762T1 (hr) | 2018-08-24 |
Family
ID=53276184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180762TT HRP20180762T1 (hr) | 2015-05-14 | 2018-05-16 | Liječenje karcinoma |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20180289733A1 (hr) |
| EP (2) | EP3197456B2 (hr) |
| JP (1) | JP6761852B2 (hr) |
| KR (1) | KR20180021697A (hr) |
| CN (2) | CN115837028A (hr) |
| AU (2) | AU2015394135B2 (hr) |
| BR (1) | BR112017024461B1 (hr) |
| CA (1) | CA2985540C (hr) |
| CY (1) | CY1120516T1 (hr) |
| DK (1) | DK3197456T3 (hr) |
| EA (1) | EA201792509A1 (hr) |
| ES (1) | ES2668377T3 (hr) |
| HR (1) | HRP20180762T1 (hr) |
| HU (1) | HUE038541T2 (hr) |
| IL (1) | IL255591B (hr) |
| LT (1) | LT3197456T (hr) |
| MX (2) | MX2017014544A (hr) |
| MY (1) | MY192081A (hr) |
| PH (1) | PH12017502086A1 (hr) |
| PL (1) | PL3197456T3 (hr) |
| PT (1) | PT3197456T (hr) |
| RS (1) | RS57371B1 (hr) |
| SI (1) | SI3197456T1 (hr) |
| TR (1) | TR201806642T4 (hr) |
| WO (1) | WO2016181093A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| ES2569185T3 (es) | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| MY176133A (en) | 2012-11-16 | 2020-07-24 | Nucana Biomed Ltd | Process for preparing nucleoside prodrugs |
| SI3119794T1 (en) | 2014-06-25 | 2018-02-28 | NuCana plc | FORMULATION, COMPOSITION OF GEMCITABIN PREPARED |
| MY183198A (en) | 2014-06-25 | 2021-02-18 | Nucana Biomed Ltd | Gemcitabine prodrugs |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| PT3224268T (pt) | 2014-11-28 | 2019-09-04 | NuCana plc | Novos derivados de 3¿-desoxiadenosina com fosforamidatos de ésteres de aminoácidos em 2¿ e/ou 5¿ como compostos anticancerígenos |
| BR112018003594A2 (pt) | 2015-09-25 | 2018-09-25 | Hoffmann La Roche | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados |
| CN108135920A (zh) | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | 组合疗法 |
| SI3386998T1 (sl) | 2015-12-11 | 2022-02-28 | NuCana plc | Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| KR102566461B1 (ko) * | 2015-12-23 | 2023-08-14 | 뉴카나 피엘씨 | 조합 요법 |
| JP6898329B2 (ja) * | 2015-12-23 | 2021-07-07 | ニューカナ パブリック リミテッド カンパニー | 併用療法 |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| EP3863674A2 (en) * | 2018-10-12 | 2021-08-18 | The Regents of the University of Colorado, a body corporate | Compositions and methods for reducing cancer stem cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| ES2569215T3 (es) * | 2007-09-10 | 2016-05-09 | Boston Biomedical, Inc. | Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer |
| WO2009126310A2 (en) * | 2008-04-10 | 2009-10-15 | Massachusetts Institute Of Technology | Methods for identification and use of agents targeting cancer stem cells |
-
2015
- 2015-05-14 MY MYPI2017001657A patent/MY192081A/en unknown
- 2015-05-14 MX MX2017014544A patent/MX2017014544A/es active IP Right Grant
- 2015-05-14 DK DK15726258.5T patent/DK3197456T3/en active
- 2015-05-14 CN CN202310013004.2A patent/CN115837028A/zh not_active Withdrawn
- 2015-05-14 CN CN201580081668.6A patent/CN107835687A/zh active Pending
- 2015-05-14 PL PL15726258T patent/PL3197456T3/pl unknown
- 2015-05-14 BR BR112017024461-6A patent/BR112017024461B1/pt active IP Right Grant
- 2015-05-14 MX MX2020009154A patent/MX2020009154A/es unknown
- 2015-05-14 SI SI201530240T patent/SI3197456T1/en unknown
- 2015-05-14 EP EP15726258.5A patent/EP3197456B2/en active Active
- 2015-05-14 JP JP2018511527A patent/JP6761852B2/ja not_active Expired - Fee Related
- 2015-05-14 HU HUE15726258A patent/HUE038541T2/hu unknown
- 2015-05-14 EA EA201792509A patent/EA201792509A1/ru unknown
- 2015-05-14 LT LTEP15726258.5T patent/LT3197456T/lt unknown
- 2015-05-14 US US15/573,969 patent/US20180289733A1/en not_active Abandoned
- 2015-05-14 RS RS20180575A patent/RS57371B1/sr unknown
- 2015-05-14 PT PT157262585T patent/PT3197456T/pt unknown
- 2015-05-14 TR TR2018/06642T patent/TR201806642T4/tr unknown
- 2015-05-14 ES ES15726258.5T patent/ES2668377T3/es active Active
- 2015-05-14 WO PCT/GB2015/051438 patent/WO2016181093A1/en active Application Filing
- 2015-05-14 CA CA2985540A patent/CA2985540C/en active Active
- 2015-05-14 KR KR1020177035629A patent/KR20180021697A/ko not_active IP Right Cessation
- 2015-05-14 EP EP18164408.9A patent/EP3415149A1/en not_active Withdrawn
- 2015-05-14 AU AU2015394135A patent/AU2015394135B2/en active Active
-
2017
- 2017-11-12 IL IL255591A patent/IL255591B/en unknown
- 2017-11-16 PH PH12017502086A patent/PH12017502086A1/en unknown
-
2018
- 2018-05-16 HR HRP20180762TT patent/HRP20180762T1/hr unknown
- 2018-05-18 CY CY20181100519T patent/CY1120516T1/el unknown
-
2020
- 2020-09-22 US US17/028,314 patent/US20210100825A1/en not_active Abandoned
-
2021
- 2021-11-30 AU AU2021277614A patent/AU2021277614A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,472 patent/US20230226092A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180762T1 (hr) | Liječenje karcinoma | |
| JP2019521971A5 (hr) | ||
| JP2018515618A5 (hr) | ||
| CY1117687T1 (el) | Adcs δουοκαρμυκινης που εμφανιζουν βελτιωμενη in vivo αντινεοπλασματικη δραστικοτητα | |
| HRP20210200T1 (hr) | Kombinirana antitumorska imunoterapija | |
| MX2021006531A (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
| HRP20191461T1 (hr) | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja | |
| BR112017022861A2 (pt) | ligantes de decompostos receptores de andrógeno seletivos (sard) e métodos de utilização dos mesmos | |
| MX2019012462A (es) | Terapia combinada. | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12015501744B1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
| EA201892745A1 (ru) | Фосфорамидатные производные нуклеозида в качестве противораковых агентов | |
| BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. | |
| BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| TR201911042T4 (tr) | Sinovit Tedavisinde veya Önlenmesinde Kullanım İçin Anti-İnflamatuar Fitobesinler. | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| CO2020000526A2 (es) | Composición para su uso en la prevención y el traramiento de patologías del aparato cardiovascular | |
| MX2018006790A (es) | Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos. | |
| BR112018013256A2 (pt) | anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo | |
| CL2018000726A1 (es) | Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1 | |
| BR112016008901A2 (pt) | Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor. |